Compare ATLX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLX | ACOG |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | Brazil | Canada |
| Employees | N/A | 57 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 110.4M |
| IPO Year | 2012 | N/A |
| Metric | ATLX | ACOG |
|---|---|---|
| Price | $3.74 | $6.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 654.5K | 29.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | $139.22 |
| Revenue Next Year | $785.59 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.32 | $4.50 |
| 52 Week High | $8.25 | $10.88 |
| Indicator | ATLX | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 59.93 |
| Support Level | $3.32 | $6.46 |
| Resistance Level | $4.17 | $6.89 |
| Average True Range (ATR) | 0.28 | 0.37 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 35.72 | 72.30 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.